Natco Pharma

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE987B01026
NSEID: NATCOPHARM
BSEID: 524816

INR

932.50

-16.35 (-1.72%)

BSENSE

Dec 05

BSE+NSE Vol: 8.82 lacs

Click here to access the older version

Company CV

About Natco Pharma Ltd.

Natco Pharma Ltd.

Small Cap

Pharmaceuticals & Biotechnology

Natco Pharma Limited was originally incorporated on 19 September 1981 as private limited company as 'Natco Fine Pharmaceuticals Private Limited'. The name of the company was changed to Natco Pharma Limited and a fresh certificate of incorporation dated 30 December 1994 issued by the RoC, Andhra Pradesh.

Company Coordinates

Company Details

Natco House, Road No 2 Banjara Hills Hyderabad Telangana : 500033

Tel: 91-040-23547532

http://www.natcopharma.co.in

investors@natcopharma.co.in

Registrar Details

Venture Capital & Corporate Investments Ltd , 12-10-167,, MIG- 167,, Bharat Nagar Colony, Hyderabad

Capital Structure

Present Equity Capital

INR 35.82 Cr

Number of Shares

17.91 Cr

Face Value

INR 2.0

Date

Number
of Shares(Cr)

Equity
Capital (Rs Cr)

Shares Added

Face Value (Rs)

Reason

30-Jun-2023

17.91

35.82

-3447295

Buy Back of Shares

16-May-2022

18.26

36.51

37000

Issued under ESOP Scheme

28-Jan-2022

18.25

36.50

155000

Issued under ESOP Scheme

14-Dec-2021

18.24

36.47

27340

Issued under ESOP Scheme

29-Jan-2021

18.23

36.47

104695

Issued under ESOP Scheme

04-Jan-2021

18.22

36.45

46795

Issued under ESOP Scheme

10-Sep-2020

18.22

36.44

118360

Issued under ESOP Scheme

27-Jan-2020

18.21

36.41

180625

Issued under ESOP Scheme

27-Jan-2020

18.21

36.41

180625

Issued under ESOP Scheme

28-Sep-2019

18.19

36.38

125215

Issued under ESOP Scheme

Shareholding

Shareholding Snapshot

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 19 Schemes (2.2%)

FIIs

Held by 187 FIIs (14.09%)

Promoter with highest holding

V C Nannapaneni (15.66%)

Highest Public shareholder

Belgrave Investment Fund (2.31%)

Individual Investors Holdings

25.84%

Board of Directors

Period

Management

Designation

Remuneration

V C Nannapaneni

Managing Director

2.27 cr

G S Murthy

Chairman & Independent Directo

8.3 lacs

Rajeev Nannapaneni

Director & Chief Executive Off

2.09 cr

T V Rao

Non-Exec. & Independent Dir.

6.2 lacs

D G Prasad

Non-Exec. & Independent Dir.

5.8 lacs

Leelaa Digumarti

Non-Exec. & Independent Dir.

3.5 lacs

PSRK Prasad

Vice President & Director

1.92 cr

MUR Naidu

Non-Exec. & Independent Dir.

6.0 lacs

D Linga Rao

President & Director

3.23 cr

Pavan Bhat

Vice President & Director

5.45 cr

Venkat Ramesh

Company Sec. & Compli. Officer

Raw Materials

Raw Materials Dashboard

Raw Materials

Amount(Rs Cr)

% of RM Cost

No Data Available for Raw Material Segmentation

No Data Available

Finished Goods

Finished Goods Dashboard

Finished Goods

Amount(Rs Cr)

% of Sales Turnover

Pharmaceuticals

1,931.70

97.25%

Other Operating Revenues - Export Incentives

29.70

1.50%

Other Operating Revenues - Jobwork Charges

15.00

0.76%

Pharmaceuticals

Other Operating Revenues - Export Incentives

Other Operating Revenues - Jobwork Charges

Stock DNA

Revenue and Profits:

Net Sales:

1,363 Cr

(Quarterly Results - Sep 2025)

Net Profit:

518 Cr

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 16,737 Cr (Small Cap)

P/E

11.00

Industry P/E

Dividend Yield

0.53%

Debt Equity

-0.34

Return on Equity

17.79%

Price to Book

1.96